ストックスクリーナーアプリを入手
13.70
4.93%
-0.7137
前日終値:
$14.41
開ける：
$14.41
24時間の取引高:
371.05K
Relative Volume:
0.42
時価総額：
$1.30B
収益：
-
当期純損益:
$-249.31M
株価収益率:
-4.1379
EPS:
-3.31
ネットキャッシュフロー:
$-209.70M
1週間 パフォーマンス:
-2.91%
1か月 パフォーマンス:
-19.32%
6か月 パフォーマンス:
-37.53%
1年 パフォーマンス:
-41.50%
1日の値動き範囲:
$13.60
$14.59
1週間の範囲:
$13.60
$14.68
52週間の値動き範囲:
$12.62
$32.52
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
名前
Rocket Pharmaceuticals Inc
セクター
電話
646-440-9100
住所
350 FIFTH AVENUE, NEW YORK, NY
RCKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
13.69 | 1.30B | 0 | -249.31M | -209.70M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.78 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.56 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.09 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.53 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 開始されました | Morgan Stanley | Overweight |
| 2022-11-08 | 開始されました | Canaccord Genuity | Buy |
| 2022-11-01 | 開始されました | BTIG Research | Buy |
| 2022-07-08 | 開始されました | Raymond James | Outperform |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2021-02-18 | 開始されました | Needham | Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-12-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 開始されました | JP Morgan | Overweight |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2019-11-06 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-26 | 開始されました | Piper Jaffray | Overweight |
| 2019-04-23 | 開始されました | Robert W. Baird | Outperform |
| 2019-03-15 | 開始されました | BofA/Merrill | Buy |
| 2019-02-05 | 開始されました | Oppenheimer | Outperform |
| 2018-09-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-07-10 | 開始されました | William Blair | Outperform |
すべてを表示
Rocket Pharmaceuticals Inc (RCKT) 最新ニュース
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT) - Seeking Alpha
RCKT (Rocket Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 30, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
RCKT (Rocket Pharmaceuticals) PE Ratio without NRI : At Loss (As of Nov. 29, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Nov. 28, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) 50-Day SMA : $16.76 (As of Nov. 28, 2024) - GuruFocus.com
Acuta Capital Partners LLC Sells 60,370 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
3 Small-Cap Stocks That Are Ready to Rocket Higher - sharewise
Fiverr International Ltd (FVRR-N) QuotePress Release - The Globe and Mail
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference - BioSpace
Rocket Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock eyes $1B+ peak sales - Investing.com
(RCKT) Long Term Investment Analysis - Stock Traders Daily
Westfield Capital Management Co. LP Acquires 165,911 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.3%Time to Buy? - MarketBeat
Leerink Partnrs Has Strong Outlook for RCKT FY2025 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital - Defense World
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline - TipRanks
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - AOL
Leerink Partners Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00 - MarketBeat
Rocket Pharmaceuticals' (RCKT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Buy Rating from Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals shares hold strong with Buy rating By Investing.com - Investing.com UK
First Turn Management LLC Purchases 60,317 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharma reports promising Phase 1 results for Danon disease therapy - Investing.com Australia
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - Asianet Newsable
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (RCKT) Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data - StreetInsider.com
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire
Rocket Pharmaceuticals is Now Oversold (RCKT) - Nasdaq
When (RCKT) Moves Investors should Listen - Stock Traders Daily
Chardan Capital Has Strong Estimate for RCKT FY2024 Earnings - MarketBeat
RCKT stock touches 52-week low at $15.96 amid market challenges - Investing.com India
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharma to Present Groundbreaking Danon Disease Gene Therapy Data at AHA 2024 | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $51.75 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Rocke - GuruFocus.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - BioSpace
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Yahoo Finance
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance
Rocket Pharmaceuticals Inc (RCKT) 財務データ
収益
当期純利益
現金流量
EPS
1.04%
0.47%
大文字化:
|
ボリューム (24 時間):